This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Reddy's Launches Debiopharm's Pamorelin® LA In India For The Treatment Of Locally Advanced Or Metastatic, Hormone-Dependent Prostate Cancer

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

About Debio R.P.

Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny ( Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA ( Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA ( South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.

About Dr.  Reddy's 

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) (Dr. Reddy's) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.

For more information, log on to: http://www.drreddys.com

Debiopharm  S.A.  Contact Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 mwagner@debiopharm.com Dr.  Reddy' s Contact S. Rajan rajans@drreddys.com Tel.: +91-40-49002445 Additional Media Contacts In  London Maitland Brian Hudspith Tel.: +44(0)20-7379-5151 bhudspith@maitland.co.uk In  New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel.: +1-212-845-4292 Fax: +1-212-845-4260 martina.schwarzkopf@russopartnersllc.com Investors and Financial Analysts: Kedar Upadhye kedaru@drreddys.com Tel.: +91-40-66834297 Saunak Savla saunaks@drreddys.com Tel.: +91-40-49002135 Milan Kalawadia ( USA) mkalawadia@drreddys.com Tel.: +1-908-203-4931

SOURCE The Debiopharm Group

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs